Clinical Study Repair

The Core Problem

This wasn’t one issue—it was a system failure:

• No ownership of the clinical study
• Broken data integrity
• Regulatory non-compliance across multiple areas

At that point, the study couldn’t support FDA submission—or even pass basic scrutiny.

The RQMIS Intervention

RQMIS stepped in and essentially became the clinical department overnight.

1. Re-establish control

• Took over clinical management of the study
• Restored active communication with the FDA
• Reconnected with study sites

2. Rebuild the infrastructure

• Reconstructed the Trial Master File (TMF) using a standardized model
• Identified, collected, and organized critical documents
• Created both paper and electronic TMF systems

3. Fix the data (this is the hard part)

• Rebuilt the clinical database from scratch
• Cleaned and re-entered all data from case report forms (CRFs)
• Implemented a streamlined query resolution process

Result: Faster, cleaner, and auditable data.

4. Reinstate safety oversight

• Re-established the Data Safety Monitoring Board (DSMB)
• Reviewed and adjudicated all adverse events (AEs/SAEs)

5. Restart study execution

• Re-engaged radiographic core lab and completed missing analyses
• Deployed monitors to re-align study sites
• Improved communication and compliance across all locations

6. Rebuild FDA relationship

• Submitted Annual Reports to re-engage the FDA
• Brought the agency back up to speed on study status
• Re-established regulatory credibility

The Outcome

• Study brought back into full regulatory compliance
• Data integrity restored
• FDA communication re-established
• Clinical operations fully functional again

And all of this was achieved in under two years

What This Actually Proves

This wasn’t just “support”—this was rescuing a failing clinical program.

Key lessons:

1. Clinical studies don’t fail overnight—they unravel quietly
Lose oversight, and everything starts drifting.

2. Data integrity is everything
If your data isn’t clean and traceable, it’s worthless to regulators.

3. FDA communication is not optional
Silence = risk.

4. You need ownership
A study without a clear clinical lead will collapse.

Where Companies Get Burned

• Assuming CROs will “just handle it”
• Neglecting TMF and documentation
• Delaying FDA communication
• Underestimating how fast compliance gaps compound

Positioning This (if you’re using it commercially)

This isn’t a “clinical services” story.

It’s:

• Turning a non-compliant, unmanaged study into a regulatory-ready asset
• Rebuilding trust with the FDA
• Salvaging millions in sunk clinical costs

Straight Talk

A broken clinical study doesn’t just delay approval—it can kill the entire product.

Fixing it requires more than management.
It requires control, structure, and regulatory credibility.